Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
PR Newswire•17/08/2026•13:41 ET
0
Whiz Insights
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, Aug. 17, 2026 /PRNewswire/ -- Ademi LLP is investigating Fulcrum (Nasdaq: FULC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Slate Medicines.
Get started
Create a free account to read the full story.